查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1133510

全球瘧疾疫苗市場2022~2029

Global Malaria Vaccines Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

主要驅動因素是瘧疾流行率上升、各種生物技術和製藥公司加大研發力度，以及政府主導的瘧疾疫苗意識提高，這些有望推動市場增長。我來了。

預計全球瘧疾流行率上升將推動市場增長。

全球瘧疾發病率上升將在預測期內提振市場。例如，根據世界衛生組織 (WHO) 的數據，2022 年全球將觀察到約 2.41 億例病例，其中將記錄 627 萬例死亡。 2020 年，非洲地區再次成為全球瘧疾負擔的最高份額，該地區佔瘧疾病例的 95%，死亡人數的約 96%。在撒哈拉以南非洲，每年約有 260,000 名 5 歲以下兒童死於瘧疾，它仍然是兒童疾病和死亡的主要原因。

該疫苗由葛蘭素史克 (GSK) 和瘧疾疫苗倡議 (MVI) 在蓋茨家庭基金會的資助下開發，稱為 RTS,S。該疫苗是世界衛生組織 (WHO) 於 2021 年 10 月推薦的第一種在兒童中“廣泛使用”的瘧疾疫苗。

R21/Matrix-M 是目前最有效的瘧疾疫苗，在第一項研究中證實有 77% 的功效。它是第一個符合世界衛生組織要求的有效率75%或以上的瘧疾疫苗的疫苗。與牛津大學、倫敦衛生和熱帶醫學學院、肯尼亞醫學研究所、印度血清研究所、Novavax 和布基納法索 Nanoro 健康科學研究所合作開發。與 RTS,S 疫苗相比，這種 R21 疫苗使用了更高百分比的環子孢子蛋白 (CSP) 抗原。

與瘧疾疫苗製造相關的限制因素阻礙了市場增長

缺乏開發人員、缺乏傳統市場以及製造疫苗反寄生蟲的技術困難可能是瘧疾疫苗生產面臨的挑戰。疾病控制和預防中心於 2021 年 10 月發布的一份報告指出，“瘧疾寄生蟲的遺傳複雜性有數千種潛在抗原。”與已經有有效疫苗接種的疾病相比，接觸瘧原蟲不會帶來終身□□免疫。 “因此，從上述陳述來看，我們預計市場在預測期內將受到阻礙。

全球瘧疾疫苗市場報告將提供對大約 40 多個市場數據表、45 多個數字和 200 多頁（大約）的訪問。

內容

第一章市場研究方法和範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第 4 章市場動態

  • 市場影響因子
    • 驅動程序
      • 生物製藥公司和製藥公司的研發活動
    • 約束因素
      • 與瘧疾疫苗相關的限制
    • 商機
    • 影響分析

第五章行業分析

  • 波特五力
  • 未滿足的需求
  • 流行病學
  • 供應鏈分析
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按傳染病類型

  • 惡性瘧原蟲
  • 按蚊種類
  • 間日瘧原蟲
  • P. 瘧疾
  • 其他

第 8 章疫苗類型

  • 紅細胞
  • 紅細胞生成促進劑
  • 多抗原
  • 其他

第 9 章，最終用戶

  • 醫院
  • 專科診所
  • 零售藥房
  • 其他

第 10 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 11 章競爭格局

  • 主要發展和戰略
  • 公司份額分析
  • 產品基準
  • 值得關注的重點公司列表

第 12 章公司簡介

  • 葛蘭素史克 (GSK)
    • 公司概況
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Sanaria
  • Nobelpharma
  • The Swiss Serum Institute
  • VLP Therapeutics LLC
  • Serum Institute of India
  • CellFree Sciences
  • Novavax
  • Bharat Biotech
  • Kenya medical research institute

第 13 章瘧疾疫苗全球市場DataM

簡介目錄
Product Code: DMPH884

Market Overview

Malaria Vaccines Market size was valued at US$ 33.29 million in 2021 and is estimated to reach US$ 327.41 million by 2029, growing at a CAGR of 31.85% during the forecast period (2022-2029).

Malaria an intermittent and remittent fever caused by a protozoan parasite that invades the red blood cells and is transmitted by mosquitoes in many tropical and subtropical regions and leads to severe illness in both pediatrics and adults. Malaria often causes severe disease, including shivering chills, high fevers, and flu-like symptoms. Humans are infected by four different types of malaria parasites Plasmodium falciparum, species of Anopheles, P. ovale, P. vivax, and P. malaria. Malaria vaccines are considered amongst the most important modalities for the prevention of malaria disease and the reduction of malaria transmission.

Market Dynamics

The major driving forces are the rising incidence of malaria cases, increase in research and development by various biotechnology or pharmaceutical companies and increasing government initiatives for malaria vaccines awareness are expected to drive market growth.

The rising incidences of malaria globally is expected to drive the market growth

The rising incidences of malaria cases globally are boosting the market over the forecast period. For instance, according to the World Health Organisation, around 241 million cases were observed globally out of which 6,27,000 deaths were recorded in 2022. African region again shows highest malaria burden share globally in 2020, 95% malaria cases with around 96% deaths were accounted by this region. In sub-Saharan Africa, it continues to be greatest cause of sickness and mortality in children as it claims around 260,000 lifes of African kids every year with age around 5 years or below.

The most recent recombinant vaccine to be created was RTS,S, which was created by GlaxoSmithKline (GSK) and Malaria Vaccine Initiatives (MVI) with funding from the the Gates Family Foundation. The vaccine is the 1st malaria vaccine to be recommended for "wide use" in children by World Health Organization in October 2021.

R21/Matrix-M is currently the most efficient malaria vaccine, with first studies showing 77% efficacy. This is the first vaccination that satisfies the WHO's requirement for a malaria vaccine to have at least a 75% effectiveness rate. The University of Oxford, London School of Hygiene and Tropical Medicine, Kenya Medical Research Institute, Serum Institute of India, Novavax and Institute of Research in Health Sciences in Nanoro, Burkina Faso collaborated to create it. Compared to the RTS,S vaccine, this R21 vaccine utilizes a larger proportion of the circumsporozoite protein (CSP) antigen.

The limitations associated with the malaria vaccines production will hamper the growth of the market

The scarcity of developers, traditional market's lack and the technical difficulty of creating a vaccine counter parasite can be the challenges for the production of a malaria vaccine. In October 2021 the Centre for diseaese control and prevention published a report where they stated that "The genetic complexity of malaria parasites results in thousands of possible antigens. Encounter with plasmodium parasites does not provide lifetime immunity, in contrast to diseases for which there are already effective vaccinations." Therefore, from the above statements, the market is expected to get hampered in the forecast period.

Segment Analysis

The plasmodium falciparum segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The plasmodium falciparum segment is expected to boost the global malaria vaccine market, owing to the increased number of incidences leading to growing research activities. Due to the high incidence by Plasmodium falciparum malaria infection cases, it is anticipated to maintain a dominating position in the worldwide malaria vaccines market in forecasr period. For instance, plasmodium falciparum infection is responsible for more than 90% of malaria fatality worldwide, according to data from the National Center for Biotechnology Information published in August 2021, and thus continues to pose a serious threat to public health on a global scale. RTS,S/AS01 is the potential vaccine for P. falciparum malaria prevention that has undergone the most extensive testing; it targets immune responses against primary circumsporozoite protein (PfCSP) that covers the infecting sporozoite's surface.

Geographical Analysis

North America region holds the largest market share of the global malaria vaccines market

North America dominates the market for malaria vaccine and is expected to show a similar trend over the forecast period owing to the rising incidences of malaria and the rapid research and development of innovative, advanced vaccines development for malaria. According to Pan America Health Organization (PAHO) report 2022, around 600,000 cases of malaria were reported in 2020 by 18 endemic American countries. That shows reduction of 26% from last year. In 2018 Paraguay, got malaria-free certification and El Salvador also received malaria-free certification in 2021.

Ongoing research and development activities are expected to boost the market. For instance, in Dec 2021, VLP Therapeutics Inc., biotech company that is based in United States collaborated for infectious disease vaccination manufacturing and distribution with Nobelpharma Ltd.

Competitive Landscape

The malaria vaccines market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market are Major key players in malaria vaccines market are GlaxoSmithKline Biologicals (GSK), the Swiss Serum Institute, WRAIR, Sanaria, BioNTech, Nobelpharma, CellFree Sciences, Sumaya Biotech, VLP Therapeutics LLC, Bharat Biotech, Serum Institute of India, Novavax, Kenya medical research institute. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the Malaria Vaccines market globally. For instance, in Sep 2021, Serum Institute of India subsidiary, Serum Institute Life Sciences announced its alliance with Biocon Biologics Limited. Under this alliance they will manufacture and commercialize variety of vaccines and antibodies targeting infectious diseases.

In Jun, 2022, BioNTech announced the initiation of construction of its first African facility for manufacturing of m-RNA Vaccine. They will manufacture m-RNA vaccines along with the development of malaria vaccine candidate.

GlaxoSmithKline Biologicals:

Overview:

GSK is a multinational biopharmaceutical business with the aspiration and mission to combine talent, science, and technology in order to conquer disease. They concentrate on four treatment fields: cancer, immunology, oncological disorders, and HIV. Prioritizing vaccination and specialty drug innovation will maximize the growing prospects for disease prevention and treatment.

Product Portfolio:

RTS, S/AS01 (Mosquirix): This is a recombinant vaccine for malaria that was created utilizing DNA from outer glycoprotein of the malaria parasite known as P. falciparum, a part of the hepatitis B virus, and an adjuvant to stimulate the immune system. Mosquirix is its name for commercial purpose. Elevated antibody titers that stop the parasite from invading the liver and helps to avoid infection.

Key Developments: In Oct 2021, Mosquirix vaccine became the first malarial vaccine to be recommended for "wide use" in children by World Health Organization.

The global malaria vaccines market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

1. Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The increase in research and development by biopharmaceutical and pharmaceutical companies
    • 4.1.2. Restraints:
      • 4.1.2.1. Limitations associated with the malaria vaccines
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces
  • 5.2. Unmet Needs
  • 5.3. Epidemiology
  • 5.4. Supply chain Analysis
  • 5.5. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type of infectious agents

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of infectious agents
    • 7.1.2. Market Attractiveness Index, By Type of infectious agents
  • 7.2. Plasmodium Falciparum
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Species of Anopheles
  • 7.4. P. vivax
  • 7.5. P. malaria
  • 7.6. Others

8. By Type of Vaccines

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of vaccines
    • 8.1.2. Market Attractiveness Index, By Type of vaccines
  • 8.2. Erythrocytic
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Pre erythrocytic
  • 8.4. Multi antigen
  • 8.5. Others

9. By End user

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 9.1.2. Market Attractiveness Index, By End user
  • 9.2. Hospitals
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Specialty Clinics
  • 9.4. Retail Pharmacy
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of infectious agents
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Vaccines
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of infectious agents
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of vaccines
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of infectious agents
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of vaccines
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of infectious agents
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of vaccines
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of infectious agents
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of vaccines
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. List of Key Companies to Watch

12. Company Profiles

  • 12.1. GlaxoSmithKline Biologicals (GSK)
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Sanaria
  • 12.3. Nobelpharma
  • 12.4. The Swiss Serum Institute
  • 12.5. VLP Therapeutics LLC
  • 12.6. Serum Institute of India
  • 12.7. CellFree Sciences
  • 12.8. Novavax
  • 12.9. Bharat Biotech
  • 12.10. Kenya medical research institute

LIST NOT EXHAUSTIVE

13. Global Malaria Vaccines Market- DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us